RecallRadar
ModerateReported July 1, 2026 (7 weeks ago)

Fenofibrate Capsules, USP 200 mg, Rx only, 100 Capsules

Recalled by Ajanta Pharma USA Inc

Product image for Fenofibrate Capsules, USP 200 mg, Rx only, 100 Capsules, Manufactured by: Ajanta Pharma Limited, India, Marketed by: Ajanta Pharma USA Inc. Bridgewater, NJ 08807, NDC 27241-120-04.
Product image via news and web sources. It may show general packaging and not the exact recalled lot — always confirm using the codes below.

Class II — moderate

Using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.

Ajanta Pharma USA Inc has recalled Fenofibrate Capsules, USP 200 mg, Rx only, 100 Capsules, according to data published by the U.S. Food and Drug Administration (FDA). The recall was reported on July 1, 2026 and was initiated on May 28, 2026. It is classified as a Class II recall, which means using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.

Below is a plain-English summary of what was recalled, why it was recalled, how to tell whether you have the affected product, and what steps you can take. For the complete and most current details, you can view the FDA record linked further down this page.

What was recalled?

This recall covers Fenofibrate Capsules, USP 200 mg, Rx only, 100 Capsules, with approximately 3648 bottles affected. The company behind the recall is Ajanta Pharma USA Inc, based in Bridgewater, NJ. The FDA describes the product as: “Fenofibrate Capsules, USP 200 mg, Rx only, 100 Capsules, Manufactured by: Ajanta Pharma Limited, India, Marketed by: Ajanta Pharma USA Inc. Bridgewater, NJ 08807, NDC 27241-120-04.”

Why was Fenofibrate Capsules, USP 200 mg, Rx only, 100 Capsules recalled?

According to the FDA, the stated reason for the recall is: “CGMP Deviations.” In plain terms, this recall relates to a manufacturing quality issue (CGMP).

CGMP stands for Current Good Manufacturing Practice — the FDA's quality rules for how medicines must be made, tested, and documented. A CGMP-related recall means the manufacturing process did not meet those standards. It does not automatically mean the medicine is harmful, but the FDA cannot be confident in its quality, so it is removed from the market.

What should you do?

If you think you may have bought Fenofibrate Capsules, USP 200 mg, Rx only, 100 Capsules, compare it against the product description and identifying codes (Lot # PA02216; Exp. 12/2029) before using it. This recall is currently listed as ongoing.

The general guidance for a matching product is to stop using it and follow the instructions in the official FDA recall notice, which may include a repair, replacement, refund, or safe disposal. When in doubt, contact Ajanta Pharma USA Inc or your local health authority.

About this recall

This recall was distributed in NJ. RecallRadar summarizes recall information from public FDA data to make it easier to understand. We are an independent service and are not affiliated with the FDA or any government agency, so please always refer to the official source for the authoritative record — and note the “last synced” date shown on this page, since recall details can change over time.

Who this recall affects

This recall matters to anyone who bought Fenofibrate Capsules, USP 200 mg, Rx only, 100 Capsules. Even if you feel fine, it's worth checking what you have on hand rather than assuming you were missed.

Distribution listed in the notice: U.S. Nationwide.

What manufacturing quality issue (CGMP) actually means

CGMP stands for Current Good Manufacturing Practice — the FDA's quality rules for how medicines must be made, tested, and documented. A CGMP-related recall means the manufacturing process did not meet those standards. It does not automatically mean the medicine is harmful, but the FDA cannot be confident in its quality, so it is removed from the market.

In this case, the concern applies specifically to Fenofibrate Capsules, USP 200 mg, Rx only, 100 Capsules from Ajanta Pharma USA Inc — not to the wider category of products. Similar items from other brands aren't part of this recall.

How to check whether you have it

On medicine bottles, the lot number and expiration date are printed on the pharmacy label or stamped directly on the manufacturer's bottle — often near the bottom edge or on the back. If a pharmacy label covers it, your pharmacist can look up the lot they dispensed.

Compare what you find against the identifying details in this recall: Lot # PA02216; Exp. 12/2029

What to do if you already bought it

Do not stop taking a prescribed medicine on your own because of a recall — for many conditions, an interrupted dose carries its own risk.

Instead, check the lot number against the details above and contact your pharmacist, who can confirm what they dispensed and arrange a replacement.

If you've had an unexpected reaction, contact your healthcare provider. Problems can also be reported to the FDA's MedWatch program.

Full recall details

Status
Ongoing
Date reported
July 1, 2026
Recall started
May 28, 2026
Distributed in
NJ
What was recalled
Fenofibrate Capsules, USP 200 mg, Rx only, 100 Capsules, Manufactured by: Ajanta Pharma Limited, India, Marketed by: Ajanta Pharma USA Inc. Bridgewater, NJ 08807, NDC 27241-120-04.
Why it was recalled (as stated by the FDA)
CGMP Deviations
How to identify the affected product
Lot # PA02216; Exp. 12/2029
Amount recalled
3648 bottles

What you can do

Check whether any product you have matches the description and codes above. If it does, stop using it and follow the instructions in the official recall notice. When in doubt, contact the company or your local health authority.

Quick answers

Why was Fenofibrate Capsules, USP 200 mg, Rx only, 100 Capsules recalled?+

According to the FDA: CGMP Deviations

How serious is this recall?+

Class II — moderate. Using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.

What should I do if I have Fenofibrate Capsules, USP 200 mg, Rx only, 100 Capsules?+

Compare your product against the description and identifying codes on this page. If it matches, stop using it and follow the instructions in the official recall notice — this usually means returning it for a refund or discarding it. When in doubt, contact the company or your local health authority.

Share this recall:PostShareEmail
View the official FDA record

Opens the U.S. Food and Drug Administration (FDA) data for this recall.

Recall number: D-0611-2026. Information last synced from the FDA on August 25, 2026.

Related recalls